Cystic fibrosis is characterized by abnormally thick mucous that clogs the lungs.
An estimated 30,000 Americans suffer from the disease. It causes chronic infection and inflammation of the lungs and can cause death in early childhood. Current treatments prevent lung inflammation by fighting infections and thinning the mucous that clogs the lungs. Now, researchers are testing inhaled gamma interferon in hopes to reduce inflammation and extend the lives of CF patients. The trial involves a new delivery system for gamma interferon.